Ekso Bionics to Report Fourth Quarter and Full Year 2024 Financial Results on March 3 – Conference Call to Follow
Ekso Bionics (Nasdaq: EKSO), a leader in exoskeleton technology for medical and industrial applications, has scheduled its fourth quarter and full year 2024 financial results announcement for March 3, 2025, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ekso Bionics (Nasdaq: EKSO), a leader in exoskeleton technology for medical and industrial applications, has scheduled its fourth quarter and full year 2024 financial results announcement for March 3, 2025, after market close. The company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss financial results and recent business developments. Investors can participate via phone by dialing 877-407-6184 (domestic) or 201-389-0877 (international). The call will also be available through a live broadcast and archive on the company's investor relations website.
Details
News Market Reaction – EKSO
The recorded move for EKSO in the trading session of this news was -3.45%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN RAFAEL, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the fourth quarter and full year 2024 after the close of trading on Monday, March 3, 2025. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to review the financial results and discuss recent business developments.
To participate in the conference call by telephone, please dial 877-407-6184 (domestic) or 201-389-0877 (international). The call will also be broadcast live and archived on the Company’s website at www.eksobionics.com under “Presentations & Events” in the Investors section.
About Ekso Bionics®
Ekso Bionics® is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical and industrial applications. Founded in 2005, the Company continues to build upon its industry-leading expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only known exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe. The Company is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol “EKSO.” For more information, visit: www.eksobionics.com or follow @EksoBionics on X.
Contact:
Stephen Kilmer
Investor Relations
Direct: (646) 274-3580
Email: skilmer@eksobionics.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.